Please use this identifier to cite or link to this item:
|Title:||Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells||Authors:||Khaw, A.K.
Glioblastoma and medulloblastoma
Histone deacetylase inhibitors
Telomeres and telomerase
|Issue Date:||2007||Citation:||Khaw, A.K., Silasudjana, M., Banerjee, B., Hande, M.P., Suzuki, M., Baskar, R. (2007). Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 625 (1-2) : 134-144. ScholarBank@NUS Repository. https://doi.org/10.1016/j.mrfmmm.2007.06.005||Abstract:||The aim of the present study is to investigate the effect of histone deacetylase inhibitor, trichostatin A (TSA) on the cell growth, apoptosis, genomic DNA damage and the expression of telomerase and associated factors in human normal and brain cancer cells. Here, human normal un-transformed fibroblasts (MRC-5), human normal hTERT-immortalised fibroblasts (hTERT-BJ1) and human brain cancer cell lines (glioblastoma cell line, A-172 and medulloblastoma cell line, ONS-76) were treated with 0.5-3.0 μM TSA for 24 h. Exposure to TSA resulted in apoptosis in a dose-dependent manner in the brain cancer cells. Glioblastoma cell line (A-172) displayed higher sensitivity to TSA-induced cell killing effect and apoptosis than the medulloblastoma cell line (ONS-76). The brain cancer cell lines and hTERT-BJ1 cell line displayed significant inhibition in telomerase activity and hTERT mRNA level after 2 μM TSA treatment. Elevated expressions of p53 and p21 with a decrease in cyclin-D level supported the observation on cell cycle arrest following TSA treatment. Upregulation of Bax and cytochrome c correlated with the apoptotic events in TSA-treated cells. This study suggests that telomerase and hTERT might be the primary targets of TSA which may have the potential to be used as a telomerase inhibitor in cancer therapy. © 2007 Elsevier B.V. All rights reserved.||Source Title:||Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis||URI:||http://scholarbank.nus.edu.sg/handle/10635/25086||ISSN:||00275107||DOI:||10.1016/j.mrfmmm.2007.06.005|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 13, 2019
WEB OF SCIENCETM
checked on Nov 13, 2019
checked on Oct 29, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.